Quote:
slcimmuno Member Level Monday, 05/15/17 12:45:47 PM
Re: Blues44 post# 182076
Post # of 182114

Phase 2 in mild-to-mod was a smaller data set (115), and not powered like the P2b is (189 patients) nor did it test in mod-to-sev, like we’re doing now (remember: more severe psoriasis patients usually see greatest changes on treatment)--and using a difft scale IGA not PASI

Prurisol in the 200mg did meet primary efficacy: 2-pt drop in IGA scale, from either starting IGA of 3 to IGA 1 or starting IGA 2 to IGA 0… Company also PR’d they saw a 3-pt drop (IGA 3 to IGA 0)

Otezla hit 30% PASI 75
Prurisol 35% of patients saw 2-pt drop on IGA
* importantly, Prurisol had 46% of moderate patients (IGA 3) have 2-pt drop to IGA 1---which again is closer to PASI 90 than PASI 75. See one of my posts from yesterday, citing a study.

So to say Prurisol didn’t match Otezla isn’t accurate. The Comparison was made harder due to use of IGA vs PASI scale in P2, but if you know what to look at, the Prurisol signal in the 200mg was v compelling… with IGA 0/1 closer to PASI 90 than PASI 75. Also, P did this in 12 weeks, not 16, like Apremilast.

Hopefully the data continues to prove out in the P2b, and will provide apple-to-apple PASI comps.

Oteza is only moderately effective and moderate on the uptake, yet generating close to $2bn year.

Prurisol has the chance to be quicker on the draw and just as good if not better.

Again – dreamland is to see 40-50% PASI 75 IMO, with robust PASI 90/100s. Encroach on those biologics and multiple Billions on tap.